Treatments used to prevent and treat male pattern baldness, the difficulty in finding a permanent cure for hair loss, and the potential financial motivations of companies not wanting to find a cure.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
OP is concerned about hairline recession and was advised by dermatologists to use Minoxidil on the hairline, despite doubts about its effectiveness there. OP is unsure about not being prescribed Finasteride and is considering whether to seek it independently.
A 28-year-old male, previously on dutasteride for hair loss, is considering oral minoxidil or a compounded treatment of minoxidil, finasteride, and tretinoin after noticing hairline recession. The dermatologist suggested oral minoxidil and mentioned a compounded option, but the user is unsure about its benefits compared to current treatments.
The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.
The user is considering using Tacrolimus Solution and topical Dutasteride to avoid shedding caused by Minoxidil, which they fear may lead to facial side effects. They are also concerned about scalp sensitivity and are exploring different treatment bases to manage seborrheic dermatitis.
A 29-year-old male experienced hair thinning and used topical minoxidil, finasteride, and RU58841, but stopped RU58841 due to health concerns. He is considering adding topical dutasteride and switching to oral minoxidil to enhance regrowth, while others suggest using ketoconazole shampoo, microneedling, and lifestyle changes like diet and exercise.
Dutasteride may inhibit androgen receptors in addition to reducing DHT, potentially explaining its effectiveness over finasteride for hair loss. Concerns about its impact on muscle growth are debated, with some suggesting no significant effects.
Exosomes are discussed as a new hair loss treatment, but skepticism is expressed about their effectiveness. Other treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses adding either RU58841 or pyrilutamide to a hair loss treatment regimen that already includes oral dutasteride and oral minoxidil. RU58841 is considered the stronger anti-androgen but may have more side effects.
A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
The user has been using minoxidil, finasteride, a laser cap, and ketoconazole shampoo for hair loss without success and is seeking advice on further tests or treatments. They have a family history of hair loss and have not yet undergone dermatologist or trichology tests.
The user reports losing a significant amount of hair when applying RU58841 and Minoxidil but loses much less hair when massaging or brushing without these treatments. They are concerned about the increased hair loss associated with these products.
The conversation discusses the appearance and testing of RU58841 powder for hair loss treatment. Users also mention side effects of RU58841 and suggest alternatives like dutasteride and minoxidil.
The conversation is about comparing the effectiveness of Minoxidil alone versus Minoxidil combined with other substances like Tretinoin, LCLT, Procapil, Aminexil, and Capixyl for hair growth. One user did not understand the terms used.
A 25-year-old male is experiencing advanced hair loss and is using topical and oral minoxidil, topical finasteride, and vitamin D3, but has not seen significant regrowth. He is considering switching treatments, including oral dutasteride, topical spironolactone, and possibly a scalp biopsy to better understand his condition.
A dermatologist checked for hereditary hair loss using blood tests and plans to perform a trichogram. The user had slightly low Vitamin D3 levels, and the trichogram may help confirm androgenetic alopecia.
The user is experiencing hair loss, possibly due to androgenic alopecia or telogen effluvium, and is considering treatments like Minoxidil, Finasteride, or RU58841. They also mention potential iron deficiency and sleep deprivation as contributing factors.
Alternating between finasteride and dutasteride is being considered due to cost concerns. The user is worried about losing progress if switching entirely to dutasteride.
The conversation is about the effectiveness of hair loss treatments, specifically finasteride and dutasteride, in different populations. Some users believe that the results of Japanese studies may not be relevant to Caucasian men, especially young ones, and that East Asians may respond better to these treatments. Others argue that clinical studies should be the basis for decision-making, while acknowledging that individual responses to medications can vary.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Clascoterone, an acne treatment that blocks DHT, is being developed for scalp use against hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
A 19-year-old male suspects his hair loss is due to vitamin D deficiency and stress rather than genetics. Recommendations include taking finasteride, minoxidil, vitamin D, exercising, reducing stress, and consulting a doctor if needed.
Finasteride users cannot donate blood due to potential risks to pregnant women, requiring a one-month cessation before donating. Dutasteride requires a six-month deferral, and topical applications are not restricted.
A 20-year-old male has been experiencing hair loss for three years due to a vitamin D deficiency and has seen no improvement after 3.5 months of taking supplements. Another person suggested that if the hair loss follows a pattern, it might be regular baldness rather than due to the deficiency.
The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.
A user discusses using tazarotene to enhance minoxidil's effectiveness for hair regrowth, believing it will make a significant difference. Others caution about potential risks of retinoids accelerating hair loss in some individuals.
The conversation discusses finding sources of Dutasteride in Europe for mesotherapy to treat hair loss. It also mentions using Minoxidil, Finasteride, and RU58841 as treatments.